Centre François-Baclesse, avenue du Général Harris, 14076 Caen Cedex 5, France.
Expert Opin Biol Ther. 2010 Apr;10(4):615-30. doi: 10.1517/14712591003689964.
Granulocyte colony-stimulating factors (G-CSFs) such as lenograstim have improved the management of cancer patient treatments for 15 years. Their use in preventing chemotherapy-induced febrile neutropenia and for progenitor-cell transplantation has been evaluated. Although the main indications are nowadays defined in academic guidelines, some changes in traditional G-CSF use are being induced by the emergence of new chemotherapy schedules and new drugs.
Analyzing publications on G-CSFs and lenograstim identified in the PubMed database from 1985 to date, we summarise pharmacological data and clinical trials on lenograstim and discuss its effects and limits in current treatment regimens.
Lenograstim is a glycosylated form of recombinant human G-CSF, more similar to the endogenous cytokine. Clinical trials have proven its efficacy for preventing chemotherapy-induced neutropenia and for progenitor-cell transplantation, almost similar to filgrastim. Its benefit is compelling in some well-defined settings (highly myelosuppressive chemotherapy, advanced cancer, high-risk patients).
If usual indications are well defined nowadays, further investigations are still needed to better define optimal use (optimal time to start, treatment duration) and effects on quality of life. In addition, since new strategies for cancer management are emerging, such as oral chemotherapy or targeted therapies, there is a need for clinical data to define lenograstim use in these recent settings.
粒细胞集落刺激因子（G-CSFs）如 lenograstim 已经改善了 15 年来癌症患者治疗的管理。已经评估了它们在预防化疗引起的发热性中性粒细胞减少症和祖细胞移植中的作用。尽管主要适应症如今在学术指南中已有定义，但由于新的化疗方案和新药的出现，传统 G-CSF 用途的一些变化正在发生。
从 1985 年至今，通过分析 PubMed 数据库中关于 G-CSF 和 lenograstim 的出版物，我们总结了 lenograstim 的药理学数据和临床试验，并讨论了其在当前治疗方案中的作用和局限性。
Lenograstim 是重组人 G-CSF 的糖基化形式，与内源性细胞因子更相似。临床试验已经证明了它在预防化疗引起的中性粒细胞减少症和祖细胞移植中的疗效，几乎与 filgrastim 相当。在某些明确的情况下（高度骨髓抑制化疗、晚期癌症、高危患者），它的益处是令人信服的。
如果目前已经明确了常见的适应症，仍需要进一步的研究来更好地定义最佳用途（开始的最佳时间、治疗持续时间）和对生活质量的影响。此外，由于癌症管理的新策略正在出现，如口服化疗或靶向治疗，因此需要临床数据来定义 lenograstim 在这些新环境中的用途。
